Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous Mast Cell Tumor in Dogs

Lucas Cavalli Kluthcovsky, Bruna Fernanda Firmo, Pedro Carvalho Cassino, Andrigo Barboza De Nardi, Jorge Luiz Costa Castro, Renata Luiza Halila, Jair Rodini Engracia Filho

Abstract


Background: Mast cell tumors (MCT) are among the most common malignant cutaneous neoplasm in dogs with variable biologic behavior and remain a therapeutic challenge in high-grade cases. Surgery remains the primary treatment for canine MCT; however, chemotherapy and radiation therapy are commonly used to treat aggressive cases. The combination of vinblastine (VBL) at a dose of 2 mg/m² and prednisone is the classically described protocol for MCT treatment. Studies have shown the safety of higher VBL doses for dogs with MCT, but there is a lack of information regarding dose intensity and outcome as a goal after chemotherapy.   This study aimed to evaluate the impact of a higher dose of VBL on MCT treatment outcome.

Materials, Methods & Results: This was an observational and comparative study conducted in two different Veterinary Teaching Hospitals. Client-owned dogs with histopathological diagnosis of grade II or III MCT were selected and underwent at least four chemotherapy sessions with VBL and prednisone. The experimental group (EG) consisted of 18 dogs that received a dose of 3 mg/m² VBL treated in one institution. The control group (CG) included 31 dogs that received a dose of 2 mg/m² VBL treated at the other institution. All dogs treated in both groups had a clinical and complete blood count (CBC) evaluation performed previous the start of chemotherapy (T0) and before each weekly treatment (T1, T2, T3, and T4). After treatment, dogs in both groups were followed-up for the recurrence rate and overall survival time after diagnosis. There was no significant difference in clinical variables between EG and CG. During treatment, dogs of EG showed a significant reduction in erythrocyte, hemoglobin, and hematocrit values between T0 and T1, T2, T3, and T4 (P < 0.001). Comparatively, the CG showed significant reduction in hemoglobin (P = 0.02) and total leucocytes (P = 0.001) values in the same period. Despite these findings, these hematological parameters did not exceed the lower limit for the species in both groups. There was a higher-grade neutropenia one week after the first VBL application (T2) in both groups, with no statistical difference in neutrophil counts at T2 or during the whole treatment. There were discrete and self-limited episodes of anorexia, vomiting, and diarrhea in both groups. After chemotherapy, dogs in EG showed a significantly lower rate of recurrence than dogs in CG (P = 0.02). There was no significant difference in the overall survival time between groups.

Discussion: The absence of significant differences in clinical variables (e.g. sex, age, histological grading, and tumor location) between EG and CG suggests that the groups may be similar regarding these parameters. All dogs included in this study had a recommendation for MCT post-operative chemotherapy treatment. VBL action is non-selective and anemia is not a commonly described adverse effect associated with its administration. Despite that, EG dogs exhibited a reduction in erythrocytes, hematocrit, and hemoglobin, and CG dogs in hemoglobin throughout T0 to T4. The highest number of neutropenia episodes occurred during T2, after the first VBL application in both groups with a trend of stabilization after T2, which is compatible with findings described in the literature. Any dog of EG or CG had to interrupt the treatment due to hematological or gastrointestinal toxicity or died during treatment. The role of VBL dose intensity in outcome is still debatable for dogs with MCT, once it is a multifactorial disease with variable presentation. In this study, there was no difference in overall survival time after diagnosis between groups, and EG dogs treated with a higher VBL dose showed significantly less tumor recurrence than CG.


Full Text:

PDF

References


Bailey D.B., Rassnick K.M., Kristal O., Chretin J.D. & Balkman C.E. 2008. Phase I dose escalation of single-agent vinblastine in dogs. Journal of Veterinary Internal Medicine. 22(6): 1397-1402.

Blackwood L., Murphy S., Buracco P., DeVos J.P., De Fornel-Thibaud P., Hirschberger J., Kessler M., Pastor J., Ponce F., Savary-Bataille K. & Argyle D.J. 2012. European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology. 10(3): e1-e29.

Davies D.R., Wyatt K.M., Jardine J.E., Robertson I.D. & Irwin P.J. 2004. Vinblastine and prednisolone adjunctive therapy for canine cutaneous mast cell tumors. Journal of the American Animal Hospital Association. 40(2): 124-130.

Harding K., Bergman N., Smith A., Lindley S., Szivek A., Milner R., Brawner W. & Lejeune A. 2018. Response rate to single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma. Veterinary and Comparative Oncology. 16(4): 636-641.

Hayes A., Adams V., Smith K., Maglennon G. & Murphy S. 2007. Vinblastine and prednisone chemotherapy for surgically excised grade III canine cutaneous mast cell tumors. Veterinary and Comparative Oncology. 5(3): 168-176.

Horta R.S., Lavalle G.E., Monteiro L.N., Souza M.C., Cassali G.D. & Araujo R.B. 2018. Assessment of canine mast cell tumor mortality risk based on clinical, histologic, immunohistochemical, and molecular features. Veterinary Pathology. 55(2): 212-223.

Kiupel M., Webster J.D., Bailey K.L., Best S., DeLay J., Detrisac C.J., Fitzgerald S.D., Gamble D., Ginn P.E., Goldschmidt M.H., Hendrick M.J., Howerth E.W., Janovitz E.B., Langohr I., Lenz S.D., Lipscomb T.P., Miller M.A., Misdrop W., Moroff S., Mullaney T.P., Neyens I., O`Toole D., Ramos-Vara J., Scase T.J., Schulman F.Y., Sledge D., Smedley R.C., Smith K., Snyder P.W., Southorn E., Stedman N.L., Steficek B.A., Stromberg P.C., Valli V.E., Weisbrode S.E., Yager J., Heller J. & Miller R. 2011. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology. 48(1): 147-155.

Miller A.G., Morley O.S., Rao S., Avery A.C., Lana S.E. & Olver C.S. 2009. Anemia is associated with decreased survival time in dogs with lymphoma. Journal of Veterinary Internal Medicine. 23(1): 116-122.

Miller RL, Lelyveld SV, Warland J, Dobson J.M. & Foale R.D. 2014. A retrospective review of treatment and response of high‐risk mast cell tumours in dogs. Veterinary and Comparative Oncology. 14(4): 361-370.

Mochizuki H., Motsinger-Reif A., Bettini C., Moroff S. & Breen M. 2016. Association of breed and histopathological grade in canine mast cell tumours. Veterinary and Comparative Oncology. 15(3): 829-839.

Mullins M.N., Dernell W.S., Withrow S.J., Ehrhart E.J., Thamm D.H. & Lana S.E. 2006. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Journal of the American Animal Hospital Association. 228(1): 91-95.

Olsen J.A., Thomson M., O`Connell K. & Wyatt K. 2018. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Veterinary Medicine and Science. 4(3): 237-251.

Patnaik A.K., Ehler W.J. & MacEwen E.G. 1984. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology. 21(5): 469-474.

Rassnick K.M., Bailey D.B., Flory A.B., Balkman C.E., Kiselow M.A., Intile J.L. & Autio K. 2008. Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine. 22(6): 1390-1396.

Rassnick K.M., Bailey D.B., Russell D.S., Flory A.B., Kiselow M.A., Intile J.L., Malone E.K., Balkman C.E. & Barnard S.M. 2010. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Veterinary and Comparative Oncology. 8(2): 138-152.

Shoop S.J., Marlow S., Church D.B., English K., McGreevy P.D., Stell A.J., Thomson P.C., O`Neill D.G. & Brodbelt D.C. 2015. Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genetics and Epidemiology. 2: 1-10.

Sledge D.G., Webster J. & Kiupel M. 2016. Canine cutaneous mast cell tumors: A combined clinical and pathologic approach to diagnosis, prognosis, and treatment selection. The Veterinary Journal. 215: 43-54.

Sorenmo K., Overley B., Krick E., Ferrara T., LaBlanc A. & Shofer F. 2010. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology. 8(3): 196-208.

Stefanello D., Buracco P., Sabattini S., Finotello R., Giudice C., Grieco V., Iussich S., Tursi M., Scase T., DiPalma S., Bettini G., Ferrari R., Martano M., Gattino F., Marrington M., Mazzola M., Elisabetta Vasconi M., Annoni M. & Marconato L. 2015. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009–2014). Journal of the American Animal Hospital Association. 246(7): 765-769.

Thamm D.H., Turek M.M. & Vail D.M. 2006. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science. 68(6): 581-587.

Varela J.C.S., Pecceu E., Handel I. & Lawrence J. 2016. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Veterinary Medicine and Science. 2(4): 266-280.

Veterinary Cooperative Oncology Group. 2016. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and Comparative Oncology. 14(4): 417-446.

Vickery K.R., Wilson H., Vail D.M. & Thamm D.H. 2008. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology. 6(2): 111-119.

Webster J.D., Yuzbasiyan-Gurkan V., Thamm D.H., Hamilton E. & Kiupel M. 2008. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Veterinary Research. 4: 32.

Wilson L., Jordan M.A., Morse A. & Margolis R.L. 1982. Interaction of vinblastine with steady-state microtubules in vitro. Journal of Molecular Biology. 159(1): 125-149.




DOI: https://doi.org/10.22456/1679-9216.101997

Copyright (c) 2020 Lucas Cavalli Kluthcovsky, Bruna Fernanda Firmo, Pedro Carvalho Cassino, Renata Luiza Halila, Andrigo Barboza De Nardi, Jorge Luiz Costa Castro, Joir Rodini Engracia Filho

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.